CEO total compensation of $11.4 million is reasonable for a clinical-stage biotech of NUVL's $8 billion market cap and is benchmarked against an industry-specific peer group; the pay mix is heavily weighted toward variable, performance-linked compensation — stock options, time-vested restricted stock units, and performance stock awards (which vest only upon achievement of specific drug development milestones) together represent the vast majority of pay, well above the 50-60% variable threshold. NUVL's 3-year stock return of +195% substantially outpaces the XBI — SPDR S&P Biotech ETF's +60.7% return, meaning above-benchmark incentive pay is well supported by shareholder outcomes; the company has a clawback policy compliant with Nasdaq standards, and prior-year say-on-pay support was a strong 83.7%, indicating no remediation concerns.

KPMG's non-audit fees (tax services of $200,824) represent about 13% of audit fees ($1,526,500), well below the 50% threshold that would raise independence concerns; tenure of approximately 6 years is far short of the 25-year threshold; KPMG is a Big 4 firm appropriate for a company of NUVL's size and complexity; and no material restatements are disclosed.